Universe Pharmaceuticals reported asset growth of -100.00% for the quarter ended Mar 2026. These growth metrics cover 10 quarters of results from Sep 2021 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Growth Metrics | Sep2021 | Mar2022 | Sep2022 | Mar2023 | Sep2023 | Mar2024 | Sep2024 | Mar2025 | Sep2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Growth Ratios | ||||||||||
| Assets Growth (1y) | 143.52% | 6.08% | -15.12% | -1.40% | 70,078,115.65% | -29.75% | -99.84% | 163,190,960.19% | 1.99% | -100.00% |
| Assets Growth (3y) | 11,214.74% | -9.76% | 889.48% | 10,316.81% | 951.92% | 0.52% | ||||
| Assets Growth (5y) | 374.53% | 1.22% | ||||||||
| Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) | -19.69% | -60.45% | 70,604.67% | -9.00% | -7.46% | -31.59% | -99.44% | 433.46% | 113,780.18% | -41.70% |
| Cash & Equivalents Growth (3y)Cash & Equiv. Growth (3y) | 706.95% | -37.33% | 53.99% | 49.19% | 80.51% | 28.61% | ||||
| Cash & Equivalents Growth (5y)Cash & Equiv. Growth (5y) | 406.69% | -5.20% | ||||||||
| Property, Plant & Equipment (Net) Growth (1y)PP&E (Net) Growth (1y) | 5.72% | 13.19% | 90,799,247.97% | -16.86% | -12.96% | 85,006,921.59% | -3.57% | -6.64% | 0.43% | 15.15% |
| Property, Plant & Equipment (Net) Growth (3y)PP&E (Net) Growth (3y) | 9,318.78% | 9,182.99% | 9,034.54% | 8,605.69% | -5.53% | 9,604.38% | ||||
| Property, Plant & Equipment (Net) Growth (5y)PP&E (Net) Growth (5y) | 1,419.22% | 1,437.81% | ||||||||
| Total Debt Growth (1y) | 63.81% | 60.66% | 90,812,561.50% | -7.55% | 39.28% | 159,657,799.67% | 45.92% | 18.76% | 15.71% | 23.58% |
| Total Debt Growth (3y) | 12,648.58% | 13,235.22% | 12,166.51% | 11,957.62% | 32.98% | 13,182.20% | ||||
| Total Debt Growth (5y) | 1,935.99% | 1,933.87% |